US COVID-19 Relief Package Boosts Pharma Manufacturing Programs – More To Come?
Executive Summary
$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.
You may also be interested in...
FDA Left Out Of $80M For Stopping Consumer Product Fraud In Latest US COVID-19 Relief Act
American Rescue Plan Act appropriated $50m to Consumer Product Safety Commission and $30.4m to Federal Trade Commission for COVID-19-related enforcement. Neither agency received funding for pandemic-related enforcement in previous relief packages.
US FDA Would See Cash Windfall In COVID-19 Relief Bill
The $500m in additional funds would support pandemic-related activities, potentially for additional staff or technology upgrades.
Initial List Of US Essential Medicines Focuses On Acute Care
US FDA excludes chronic care products from list of medicines bolstered by domestic production investment and federal procurement requirements.